Molecular imaging in oncology

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Sullivan, D C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; TUMOR MARKER;

ARTICLE; BIOLUMINESCENCE; BREAST BIOPSY; BREAST CANCER; CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DRUG RESEARCH; ESOPHAGUS CANCER; FLUORESCENCE RESONANCE ENERGY TRANSFER; FOLLOW UP; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DIAGNOSTIC IMAGING; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 33749640930     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl275     Document Type: Article

References (16)

1. Thomasson DM, Gharib A, Li K. A primer on molecular biology for imagers. Acad Rad 2004; 11 (Suppl): 85-96.
2. Danthi SN, Pandit SD, Li K. A primer on molecular biology for imagers: VII. Molecular imaging probes. Acad Rad 2004; 11 (Suppl): 77-84.
3. Min JJ, Gambhir SS. Gene therapy progress and prospects: Noninvasive imaging of gene therapy in living subjects. Gene Ther 2004; 11: 115-125.
4. Sullivan DC, Ferrari M. Nanotechnology and tumor imaging: Seizing an opportunity. Review. Mol Imaging 2004; 3: 364-369.
5. Michalet X, Pinaud FF, Bentolila LA et al. Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics Review. Science 2005; 28: 538-544.
6. Contag C, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 2002; 4: 235-260.
7. Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur Radiol 2003; 13: 195-208.
8. Louie AY, Huber MM, Ahrens ET et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000; 18: 321-325.
9. Kelloff GJ, Sigman CC. New science-based endpoints to accelerate oncology drug development. Eur J Cancer 2005; 41: 491-501.
10. Mankoff DA, Peterson LM, Petra PH et al. Factors affecting the level and heterogeneity of uptake of (18F) fluoroestradiol (FES) in patients with estrogen receptor positive (ER+) breast cancer. J Nucl Med 2002; 43: 286P.
11. Leach MO, Brindle KM, Evelhoch JL et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer 2005; 92: 1599-1610.
12. Morgan B, Thomas AL, Drevs J et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases. J Clin Oncol 2003: 21: 3955-3964.
13. Meisamy S, Bolan PJ, Baker EH et al. Predicting response to neoadjuvant chemotherapy of locally advanced breast cancer with in vivo 1H MRS: A pilot study at 4 Tesla. Radiology 2004; 233: 424-431.
14. Kelloff GJ, Hoffman JH, Johnson B et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development. Clin Can Res 2005; 11: 2785-2808.
15. Evelhoch J, Garwood M, Vigneron D et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy. Workshop Report. Cancer Res 2005; 65: 7041-7044.
16. Shankar LK, Hoffman JM, Bacharach S et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006; 47: 1059-1066.